The content on this site is intended for healthcare professionals only
PIPSeN trial: Olaparib maintenance vs placebo in platinum-sensitive non-small ce...
Dr Sophie Postel-Vinay - Gustave Roussey Cancer Center, Paris, France
4 May 2021
Efficacy and early discontinuation predictors in NSCLC patients receiving nivolu...
Dr Giulia Pasello - University of Padova, Padua, Italy
4 May 2021
OncoAlert and ecancer weekly roundup for April 19 - 25, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
26 Apr 2021
Language and understanding: The complexity of insight in cancer care
Dr Tianna Martin - Beaumont Hospital, Dublin, Ireland
22 Apr 2021
Understanding patient experience in Europe: The first Global Lung Cancer Coaliti...
Vanessa Beattie - Lung Cancer Nursing UK, Solihull, England
22 Apr 2021
CONVERT trial: Patterns of relapse following thoracic radiotherapy in patients w...
Dr Robin Portner - The Christie NHS Foundation Trust, Manchester, UK
19 Apr 2021
First-line osimertinib in EGFR mutant aNSCLC patients: Progression pattern and s...
Dr Martina Lorenzi - University of Padua, Padua, Italy
16 Apr 2021
AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-onc...
Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain
16 Apr 2021
CheckMate 9LA: First-line nivolumab, ipilimumab and 2 cycles chemotherapy vs 4 c...
Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain
16 Apr 2021
CheckMate 816 trial: Nivolumab and platinum-doublet chemotherapy vs chemo as neo...
Dr Patrick M. Forde - Johns Hopkins University, Baltimore, USA
16 Apr 2021
Efficacy and safety of selpercatinib in RET fusion-positive cancers other than l...
Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA
13 Apr 2021
First-line pembrolizumab plus chemotherapy for patients with advanced squamous N...
Dr Andrew Robinson - Cancer Centre of Southeastern Ontario at Kingston General H...
9 Apr 2021
